Bibliography
- Food and Drug Administration. FDA Response to Citizen Petition: center for Lawful Access and Abuse Deterrence (CLAAD), Docket ID FDA-2013-P-0703-0001. Available from: http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm369273.htm [Last accessed 24 January 2014]
- Food and Drug Administration. FDA Statement: original Opana ER Relisting Determination. 2013. Available from: www.fda.gov/Drugs/DrugSafety/ucm351357.htm [Last accessed 24 January 2014]
- Food and Drug Administration. Abuse-Deterrent Opioid Analgesics. Available from: www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm347569.htm [Last accessed 24 January 2014]
- Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain 2013;14(10):1122-30
- Lankenau SE, Teti M, Silva K, et al. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy 2012;23(1):37-44
- Coplan PM, Kale H, Sandstrom L, et al. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf 2013;22:1274-82
- Food and Drug Administration. FDA Briefing Information for the December 7, 2012 Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM330683.pdf [Last accessed 24 January 2014]
- Moore TJ, Furberg CD. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US Food and Drug Administration: The Class of 2008. JAMA Intern Med 2014;174(1):90-5
- Furlan A, Chaparro LE, Irvin E, Mailis-Gagnon A. A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain. Pain Res Manag 2011;16:337-51
- Sullivan MD, Howe CQ. Opioid therapy for chronic pain in the United States: promises and perils. Pain 2013;154(Suppl 1):S94-100
- American Pain Foundation Shuts Down as Senators Launch Investigation of Prescription Narcotics. Available from: www.propublica.org/article/senate-panel-investigates-drug-company-ties-to-pain-groups [Last accessed 24 January 2014]
- Nelson LS, Perrone J. Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS). JAMA 2012;308:457-8
- Juurlink DN, Dhalla IA, Nelson LS. Improving opioid prescribing: the New York City recommendations. JAMA 2013;309:879-80